STOCK TITAN

Poplar Point’s NovaBay stake at 17.52% as voting pact ends

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Poplar Point Capital and affiliates filed Amendment No. 2 to Schedule 13D on NovaBay Pharmaceuticals (NBY), disclosing beneficial ownership of 1,020,300 shares, representing 17.52% of the common stock. The group reports shared voting and dispositive power over 1,020,300 shares and no sole power.

The amendment notes that NovaBay terminated the voting agreement effective upon the vote, with an Irrevocable Notice of Termination included as an exhibit. The reporting persons state the holding is for investment purposes and, at this time, have no specific plan or proposal to acquire additional or dispose of shares. Poplar Point Capital Management LLC directly holds the 1,020,300 shares, funded from working capital.

Positive

  • None.

Negative

  • None.

Insights

Stake at 17.52% with voting pact terminated; intentions unchanged.

Poplar Point and affiliates report beneficial ownership of 1,020,300 NovaBay shares, equal to 17.52% of the class, with shared voting and dispositive power and no sole power. PPCM directly holds the shares, sourced from working capital.

The amendment highlights that NovaBay terminated the voting agreement effective upon the vote, removing a coordinated voting arrangement. The reporting group indicates the investment is for portfolio purposes and lists no current plans for additional purchases or dispositions.

Key items to watch are future ownership updates and any new governance arrangements. The Date of Event is 10/15/2025; subsequent disclosures may clarify any changes in intentions or structures.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Poplar Point Capital Management LLC
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry, Manager
Date:10/17/2025
Poplar Point Capital Partners LP
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry, Manager
Date:10/17/2025
Poplar Point Capital GP LLC
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry, Manager
Date:10/17/2025
Jad Fakhry
Signature:/s/ Jad Fakry
Name/Title:Jad Fakhry
Date:10/17/2025

FAQ

What stake in NovaBay (NBY) does Poplar Point report in this 13D/A?

They disclose beneficial ownership of 1,020,300 shares, representing 17.52% of the common stock.

What changed in governance in this NovaBay (NBY) 13D/A amendment?

The filing states NovaBay terminated the voting agreement effective upon the vote, with a termination notice included as an exhibit.

Who holds the NovaBay (NBY) shares and how were they funded?

Poplar Point Capital Management LLC directly holds 1,020,300 shares, acquired using working capital.

What voting and dispositive powers are reported for NovaBay (NBY)?

The reporting persons have shared voting and dispositive power over 1,020,300 shares and no sole power.

Do the reporting persons plan to buy or sell more NovaBay (NBY) shares?

They state the position is for investment purposes and report no specific plan or proposal to acquire additional or dispose of shares at this time.

When is the Date of Event for this NovaBay (NBY) 13D/A?

The Date of Event which requires filing is 10/15/2025.
Novabay Pharma

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Latest SEC Filings

NBY Stock Data

67.91M
6.17M
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE